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bacteremia, pneumonia, and otitis media, but costs more
than previously introduced vaccines. We determined the
savings in medical costs over 36 months of life attribut-
able to the use of the vaccine in healthy infants in a large
randomized trial.
METHODS: We analyzed the actual costs and utilization
for 36,471 children involved in a randomized trial of the
heptavalent pneumococcal conjugate vaccine conducted
in the Northern California Kaiser Permanente Medical
Care Program (KP). Costs were analyzed for all children
randomized in the trial (intent-to-treat) who were mem-
bers of the health plan at any time during the follow-up.
All clinic- and pharmacy-related costs were included, as
were those hospital costs associated with conditions
deemed to be potentially pneumococcal related. The cost
of the vaccine and vaccine administration were excluded.
Confidence intervals around cost savings were calculated
using bootstrap replications.
RESULTS: Compared with the control group, the vacci-
nated group incurred $78 less in medical costs (CI: $5 to
$158) per child during the first 36 months of life, exclu-
sive of the cost of the vaccine. This represented savings of
about 3% of total medical costs for these children during
that time period.
CONCLUSION: The pneumococcal conjugate vaccine
reduced medical costs in children in the first 36 months
of life, before factoring in the cost of the vaccine and vac-
cine administration. These cost savings, however, are un-
likely to offset the cost of the vaccine at its current price.
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OBJECTIVES: To establish the concurrent and discrimi-
natory validity, and relative item importance of the previ-
ously developed client-centered, 51-item Schizophrenia
Outcomes Assessment Project (SOAP-51) survey, a self-
administered, health-related quality of life instrument for
individuals with schizophrenia living in the community.
METHOD: We asked 1500 community-based clients
with schizophrenia, and 150 of their caregivers (using the
shortened objective version), in five ethnically and geo-
graphically diverse areas within the US to complete the
SOAP-51 four times over a three-month period; client re-
tention was 84.2%. Average age was 42.8 years, 60%
males. For concurrent validation, clients rated the impact
of their condition on each of SOAP-51’s eight factors;
this was compared to their factor score. For discriminate
validity, the caregivers assigned clients to one of four
quartiles describing their perception of the client’s ability
to objectively function in each factor area. Client factor
scores were compared to caregiver-reported functional
levels. An additional 300 clients rated the relative impor-
tance of each item.
RESULTS: Cronbach’s alpha for the eight factors was
0.71–0.88, test-retest reliability, 0.78–0.99. Client factor
scores lowered as clients felt the condition had more neg-
atively impacted on their lives (p  .001). Client factor
scores improved with improving caregiver-perceived as-
sessment of client functionality (p  .001). Client scores
from the lowest to highest assigned quartile had average
scores of 42.7%, 49.3%, 54.7%, and 60.0%, respec-
tively. Ninety two percent of both clients and caregivers
considered the survey valuable for monitoring client
progress. No significant difference (p  .05) was ob-
served in importance weights for the eight factors, or 51
items, age or gender of client, caregiver or client re-
sponses.
CONCLUSIONS: Concurrent and discriminatory valid-
ity show that the SOAP-51 meets psychometric charac-
teristics for use as a client-centered outcomes measure in
patient monitoring and management, and health policy
decision-making.
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OBJECTIVES: Because clinical outcomes of depression
treatment in primary care settings tend to be poor, we de-
veloped and evaluated the efficacy of two augmentations
to antidepressant treatment to be delivered by primary
care nurses.
METHODS: We conducted a randomized trial compar-
ing usual care, telehealth care, and telehealth care plus
peer support for depressed patients seen in primary care
in an HMO setting. Assessments were conducted at base-
line, six weeks and six months after study enrollment at
two managed-care, adult primary-care clinics. Partici-
pants included 303 patients recently started on antide-
pressants. The intervention consisted of: telehealth care;
emotional support and focused behavioral interventions
in 10 seven-minute calls over four months by specially
trained primary-care nurses and peer support; telephone
and in-person supportive contacts by trained Health Plan
members recovered from depression. Primary outcome
measures were the Hamilton Rating Scale for Depression,
Beck Depression Inventory, Mental and Physical Func-
tioning (Short Form 12), and treatment satisfaction and
medication adherence questionnaires.
RESULTS: Nurse-based telehealth patients with or with-
out peer support more often experienced 50% improve-
ment on the Hamilton at six weeks (50% vs. 37%, P 
.01) and six months (57% vs. 38%, P  .003), and on
